NR1D1 in tumorigenesis: dual roles, mechanisms, and therapeutic targeting
Gene · 2026
DOI: 10.1016/j.gene.2025.149889 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Gene, 2026. Verfasst von Zhuangwei Lv und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Forensic Medicine, Xinxiang Medical University, Xinxiang, China. Hauptthemen laut MEDLINE: Neoplasms, Carcinogenesis, Nuclear Receptor Subfamily 1, Group D, Member 1. Die Arbeit nennt 91 Literaturangaben. Gefördert von: Henan Province Natural Science Foundation, Xinxiang Medical University.
Abstract (Originalsprache)
Nuclear receptor subfamily 1, group D, member 1 (NR1D1, also known as REV-ERBα), a core circadian regulator, plays context-dependent dual roles in cancer, acting as either a tumor suppressor or oncogene. This review synthesizes current evidence on NR1D1's regulation of key oncogenic pathways: DNA repair, immunomodulation (e.g., the cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway, NOD-like receptor family pyrin domain containing 3(NLRP3)), metabolism, and signaling cascades such as PI3K/AKT, JAK/STAT. We highlight its clinical utility as a prognostic biomarker and therapeutic target, focusing on pharmacological modulators with demonstrated preclinical efficacy. We also critically discuss challenges in targeting NR1D1 and its potential in combination therapies, offering new insights for cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Forensic Medicine, Xinxiang Medical University, Xinxiang, China.
- School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, China.
- School of Junji College, Xinxiang Medical University, Xinxiang, Henan, China.
- North Henan Medical University, Xinxiang, Henan, China.
- Institutes of Health Central Plains, Xinxiang Medical University, Xinxiang 453003, China.
- School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, China; Xinxiang Engineering Technology Research Center of immune checkpoint drug for Liver-Intestinal Tumors, Xinxiang Medical University, Xinxian…
Förderung
- Henan Province Natural Science Foundation
- Xinxiang Medical University
Zitieren
APA
Lv, Z., Yang, R., Wu, J., Shi, X., Wang, R., Niu, Y., Qian, Z., Jiao, J., & Ma, Y. (2026). NR1D1 in tumorigenesis: dual roles, mechanisms, and therapeutic targeting. Gene. https://doi.org/10.1016/j.gene.2025.149889
Vancouver
Lv Z, Yang R, Wu J, Shi X, Wang R, Niu Y, et al. NR1D1 in tumorigenesis: dual roles, mechanisms, and therapeutic targeting. Gene. 2026. doi:10.1016/j.gene.2025.149889
BibTeX
@article{Lv2026,
author = {Lv, Zhuangwei and Yang, Ruohao and Wu, Jinhua and Shi, Xiaoyu and Wang, Ruihan and Niu, Yi'ang and Qian, Zhuang and Jiao, Junna and Ma, Yunfeng},
title = {NR1D1 in tumorigenesis: dual roles, mechanisms, and therapeutic targeting},
journal = {Gene},
year = {2026},
doi = {10.1016/j.gene.2025.149889}
}
EUVIMED